Pfizer Inc. said late Tuesday it received accelerated Food and Drug Administration approval for its breast cancer drug Inbrance. The approval allows marketing of the drug along with letrozole to treat postmenopausal women for a certain type of breast cancer that has spread. Pfizer said the drug is available to order immediately through specialty pharmacies. Shares of Pfizer rose 0.9% to $32.30 on moderate volume in the extended session.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below